DB18261ExperimentalGene Therapies
C134 is a genetically engineered oncolytic herpes simplex virus expressing human cytomegalovirus (HCMV) internal repeat short 1 (IRS1).
- Mechanism
- Curator reviewed
Pharmacologically active on Spermine oxidase and Peroxisomal N(1)-acetyl-spermine/spermidine oxidase
Resolves to
Targets
What you can answer from here — as of October 05, 2026
2Protein targetsEach mapped to UniProt, with action and pharmacological actionListed above
Which drugs share a target with C134, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account